Literature DB >> 20087211

Managing hypertension in obstructive sleep apnea: the interplay of continuous positive airway pressure, medication and chronotherapy.

Costas Tsioufis1, Alexandros Kasiakogias, Costas Thomopoulos, Athanasios Manolis, Christodoulos Stefanadis.   

Abstract

Hypertension is highly prevalent and usually uncontrolled among patients with obstructive sleep apnea despite multiple interventions, namely lifestyle modifications, use of antihypertensive drugs and continuous positive airway pressure application. Main prognosticators of the blood pressure (BP) reduction with continuous positive airway pressure therapy are high levels of BP, severity of apnea and daytime sleepiness. The long-term effect of continuous positive airway pressure on BP is still inconclusive, and compliance issues constitute a major limitation. There is no clear evidence for preference for a specific type of antihypertensive drug, and selection should primarily be guided by the patient's cardiometabolic profile and associated clinical conditions. Furthermore, as hypertensive patients with obstructive sleep apnea frequently exhibit a disturbed circadian BP pattern, chronotherapy emerges as a possible therapeutic supplement.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20087211     DOI: 10.1097/HJH.0b013e328336ed85

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  10 in total

Review 1.  Effect of renal sympathetic denervation on apnea-hypopnea index in patients with obstructive sleep apnea: a systematic review and meta-analysis.

Authors:  Ghanshyam Palamaner Subash Shantha; Samir Bipin Pancholy
Journal:  Sleep Breath       Date:  2014-05-17       Impact factor: 2.816

Review 2.  Clinical Diagnosis and Management of Resistant Hypertension.

Authors:  Costas P Tsioufis; Alexandros Kasiakogias; Dimitrios Tousoulis
Journal:  Eur Cardiol       Date:  2016-08

3.  Sleep apnea: secondary cause or risk factor for hypertension?

Authors:  Costas Thomopoulos; Kyriakos Dimitriadis; Alexandros Kasiakogias; Costas Tsioufis
Journal:  J Clin Hypertens (Greenwich)       Date:  2012-04-24       Impact factor: 3.738

4.  Nocturnal Hypertension Correlates Better With Target Organ Damage in Patients With Chronic Kidney Disease than a Nondipping Pattern.

Authors:  Cheng Wang; Wen-Jie Deng; Wen-Yu Gong; Jun Zhang; Qun-Zi Zhang; Zeng Chun Ye; Tanqi Lou
Journal:  J Clin Hypertens (Greenwich)       Date:  2015-06-04       Impact factor: 3.738

5.  Pathophysiology of resistant hypertension: the role of sympathetic nervous system.

Authors:  Costas Tsioufis; Athanasios Kordalis; Dimitris Flessas; Ioannis Anastasopoulos; Dimitris Tsiachris; Vasilios Papademetriou; Christodoulos Stefanadis
Journal:  Int J Hypertens       Date:  2011-01-20       Impact factor: 2.420

6.  Resistant hypertension and obstructive sleep apnea: the sparring partners.

Authors:  Costas Thomopoulos; Helena Michalopoulou; Alexandros Kasiakogias; Anna Kefala; Thomas Makris
Journal:  Int J Hypertens       Date:  2011-01-10       Impact factor: 2.420

7.  Common secondary causes of resistant hypertension and rational for treatment.

Authors:  Charles Faselis; Michael Doumas; Vasilios Papademetriou
Journal:  Int J Hypertens       Date:  2011-03-02       Impact factor: 2.420

Review 8.  The efficacy of antihypertensive drugs in chronic intermittent hypoxia conditions.

Authors:  Lucilia N Diogo; Emília C Monteiro
Journal:  Front Physiol       Date:  2014-09-22       Impact factor: 4.566

9.  A hypertensive response to exercise is prominent in patients with obstructive sleep apnea and hypertension: a controlled study.

Authors:  Alexandros Kasiakogias; Costas Tsioufis; Costas Thomopoulos; Ioannis Andrikou; Anna Kefala; Dimitrios Papadopoulos; Ioanna Dima; Anastasios Milkas; Peter Kokkinos; Christodoulos Stefanadis
Journal:  J Clin Hypertens (Greenwich)       Date:  2013-04-29       Impact factor: 3.738

Review 10.  Implications of Renal Denervation Therapy in Patients with Sleep Apnea.

Authors:  Fernando Jaén-Águila; José Antonio Vargas-Hitos; Juan Diego Mediavilla-García
Journal:  Int J Hypertens       Date:  2015-09-30       Impact factor: 2.420

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.